Quintiles, a US-based biopharma services company offering clinical, commercial, consulting and capital solutions, has expanded its drug research unit at Guy’s Hospital in London.
Subscribe to our email newsletter
Quintiles said that the expansion of the facility was the result of the collaboration with two UK-based institutions Guy’s and St Thomas’ NHS Foundation Trust and King’s College London.
Reportedly, the expanded facility consists of 35 beds for both patients and healthy volunteers and increases capacity to conduct proof-of-concept programs.
The expansion brings Quintiles physically and professionally closer to academic and medical colleagues in the Academic Health Sciences Centre (AHSC), King’s Health Partners, and the National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre (BRC), said Quintiles.
The Quintiles Drug Research Unit at Guy’s Hospital is positioned next to Clinical Research Facilities and a Good Manufacturing Practice (GMP) Pharmacy currently being developed by Guy’s and St Thomas’ and King’s College London to drive forward the translation of science onto the wards – from ‘bench to bedside’ – and is also expected to be adjacent to the home of the BRC’s new Faculty of Translational Medicine.